FDA warned Gadal Laboratories of CGMP violations at its Miami drug plant, including unqualified suppliers and contamination risks in pediatric OTC drugs.
What happened
FDA inspected Gadal Laboratories’ Miami, Florida drug manufacturing facility from February 13 to February 17, 2023. FDA found the drugs were adulterated because manufacturing did not meet CGMP, including failures in supplier qualification, component testing, process validation, cleaning validation, and quality unit oversight. FDA reviewed the company’s March 7, 2023 response and found it inadequate.
What FDA found
Failed to qualify suppliers and validate supplier test reports for components, including an active ingredient and an excipient known as a source of Clostridium botulinum spores.
21 CFR 211.84(d)(2)Did not perform a specific identity test on every shipment, container, and lot of certain high-risk components before use.
21 CFR 211.84(d)(2)Had not completed process performance qualification studies before commercial distribution and did not investigate multiple out-of-specification assay results in a validation study.
21 CFR 211.100(a)Did not adequately qualify and test its in-house system used to produce a raw material for manufacturing and cleaning to ensure it consistently met chemical and microbiological standards.
21 CFR 211.100(a)Cleaning validation and verification were inadequate and relied only on pH testing, so cross-contamination and microbial contamination could be missed.
21 CFR 211.100(a)The quality unit failed to oversee changes and documentation, including an inactive ingredient substitution without justification or label update and raw lab data recorded in pencil or obscured with correction fluid.
21 CFR 211.22(d)
What FDA wants
FDA tells Gadal to correct the violations promptly and respond in writing within 15 working days. It also asks for remaining high-risk component and finished product test results within 30 calendar days and for risk assessments and recalls if contaminated lots are found; it recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy or distribute Gadal’s OTC drug products
- pharmacies and retailers selling pediatric OTC products
- quality teams relying on supplier certificates of analysis for high-risk components
This is a summary. Read the original letter on fda.gov.